Ampersand Capital Partners has officially completed its acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business. 

The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its state-of-the-art facility in Huntsville, Alabama.

Gannet BioChem leverages its expertise and advanced infrastructure to deliver comprehensive capabilities in the biotechnology sector. Its end-to-end GMP production process encompasses raw material sourcing, manufacturing, and packaging, ensuring consistent quality and reliability throughout the supply chain.

The facility has contributed to the development and production of PEG reagents used in nine FDA-approved therapeutics and continues to supply reagents for several marketed drugs, demonstrating its commercial impact. Designed with flexibility in mind, the facility efficiently handles both small-scale and commercial-scale production.

The team at Gannet BioChem boasts an average tenure of 13 years, reflecting their experience and dedication to maintaining high standards. The company operates a 124,000 sq. ft. facility equipped for both current operations and future expansion, with dedicated areas for small and large-scale production.

Strategically located in Huntsville, Alabama, near the USA's second-largest life sciences research park, Gannet BioChem benefits from a collaborative and innovative ecosystem. Its FDA-inspected facility upholds an excellent compliance record, reinforcing its legacy of quality and commitment to customers worldwide.

With over 30 years of expertise, Gannet BioChem is a proven specialty CDMO leader in developing, scaling, and manufacturing polyethylene glycol (PEG) reagents - critical components in advanced biopharmaceutical and therapeutic products.

"We are thrilled to introduce Gannet BioChem as a new, independent PEG reagents CDMO. The PEG reagent manufacturing team at Gannet BioChem has a well-established track record and long history of delivering high-quality, specialized PEG reagents for commercial and clinical stage biologic therapeutics.  We are well-equipped to build on that legacy with the support of Ampersand's resources and expertise in life sciences partnerships. Gannet BioChem is poised for continued success and strategic growth as a trusted partner to biopharmaceutical innovators globally," said David Anderson, General Partner at Ampersand Capital Partners.